Publications

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities  (2020)

Authors:
Luchini, Claudio; Paolino, Gaetano; Mattiolo, Paola; Piredda, Maria L; Cavaliere, Alessandro; Gaule, Marina; Melisi, Davide; Salvia, Roberto; Malleo, Giuseppe; Shin, Jae Il; Cargnin, Sarah; Terrazzino, Salvatore; Lawlor, Rita T; Milella, Michele; Scarpa, Aldo
Title:
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Year:
2020
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Format:
Elettronico
Referee:
No
Name of journal:
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
ISSN of journal:
1756-9966
N° Volume:
39
Number or Folder:
1
Page numbers:
1-10
Keyword:
BRAF; KRAS; MSI; dMMR; fusion genes; pancreatic cancer
Short description of contents:
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases.The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors with an activated MAPK pathway due to BRAF mutation that occur in up to 4% of cases. The second includes tumors with microsatellite instability (MSI) due to defective DNA mismatch repair (dMMR), which occurs in about 2% of cases, also featuring a high tumor mutational burden. The third category is represented by tumors with kinase fusion genes, which marks about 4% of cases. While therapeutic molecular targeting of KRAS is an unresolved challenge, KRAS-wild type PDACs have potential options for tailored treatments, including BRAF antagonists and MAPK inhibitors for the first group, immunotherapy with anti-PD-1/PD-L1 agents for the MSI/dMMR group, and kinase inhibitors for the third group.This calls for a complementation of the histological diagnosis of PDAC with a routine determination of KRAS followed by a comprehensive molecular profiling of KRAS-negative cases.
Note:
Published: OCT 28 2020
Product ID:
117160
Handle IRIS:
11562/1028368
Last Modified:
November 18, 2022
Bibliographic citation:
Luchini, Claudio; Paolino, Gaetano; Mattiolo, Paola; Piredda, Maria L; Cavaliere, Alessandro; Gaule, Marina; Melisi, Davide; Salvia, Roberto; Malleo, Giuseppe; Shin, Jae Il; Cargnin, Sarah; Terrazzino, Salvatore; Lawlor, Rita T; Milella, Michele; Scarpa, Aldo, KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH» , vol. 39 , n. 12020pp. 1-10

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back

Activities

Research facilities

Share